Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors. (23rd November 2022)

• Record Type: Journal Article
• Authors: Budha, Nageshwar; Wu, Chi‐Yuan; Tang, Zhiyu; Yu, Tian; Liu, Lucy; Xu, Fengyan; Gao, Yuying; Li, Ruiying; Zhang, Qiuyang; Wan, Ya; Sahasranaman, Srikumar
• Is Part Of: CPT: pharmacometrics & systems pharmacology. Volume 12:Number 1(2023)
• Page Start: 95
• Page End: 109
• Publication Date: 2022-11-23
• Subjects: Pharmacokinetics -- Periodicals; Pharmacology -- Periodicals; Pharmacokinetics; Periodicals; 615.05
• DOI: 10.1002/psp4.12880
• Languages: English
• ISSNs: 2163-8306

Abstract

Abstract: Tislelizumab, a humanized immunoglobulin G4 monoclonal antibody, is a programmed cell death protein 1 (PD‐1) inhibitor designed to minimize Fc gamma receptor binding on macrophages to limit antibody‐dependent phagocytosis, a potential mechanism of resistance to anti–PD‐1 therapy. The pharmacokinetic (PK) profile of tislelizumab was analyzed with population PK modeling using 14, 473 observed serum concentration data points from 2596 cancer patients who received intravenous (i.v.) tislelizumab at 0.5–10 mg/kg every 2 weeks or every 3 weeks (q3w), or a 200 mg i.v. flat dose q3w in 12 clinical studies. Tislelizumab exhibited linear PK across the dose range tested. Baseline body weight, albumin, tumor size, tumor type, and presence of antidrug antibodies were identified as significant covariates on central clearance, whereas baseline body weight, sex, and age significantly affected central volume of distribution. Sensitivity analysis showed that these covariates did not have clinically relevant effects on tislelizumab PK. Other covariates evaluated, including race (Asian vs. White), lactate dehydrogenase, estimated glomerular filtration rate, renal function categories, hepatic function measures and categories, Eastern Cooperative Oncology Group performance status, therapy (monotherapy vs. combination therapy), and line of therapy did not show a statistically significant impact on tislelizumab PK. These results support the use of tislelizumab 200 mg i.v. q3w without dose adjustment in a variety of patient subpopulations.